Molecular mass: 280.407 g/mol PubChem compound: 3696
Imipramine is a tricyclic antidepressant and has several pharmacological actions including alpha-adrenolytic, antihistamine, anticholinergic and 5HT-receptor blocking properties. However, the main therapeutic activity is believed to be inhibition of the neuronal re-uptake of noradrenaline and 5HT. Imipramine is a so-called “mixed” re-uptake blocker, i.e. it inhibits the reuptake of NA and 5HT to about the same extent.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N06AA02 | Imipramine | N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AA Non-selective monoamine reuptake inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| IMIPRANIME Sugar-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| TOFRANIL Sugar-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/Old |
Imipramine is an active ingredient of these brands:
United States (US)
Australia (AU)
Brazil (BR)
Estonia (EE)France (FR)
Mexico (MX)
New Zealand (NZ)
South Africa (ZA)
Spain (ES)
Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
